The OSNA assay, a new method developed in 2007, measures the tumor cell-specific expression of cytokeratin 19 (CK19) mRNA in lymph nodes and determines the presence of lymph node metastasis by comparing the level to a cut-off value. Here, KRT19 is linked to metastatic malignant neoplasm in the lymph nodes.